• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Torti appointed to FDA leadership roles

Article

The FDA announced the appointment of Frank M. Torti, MD, as its principal deputy commissioner and first chief scientist.

The FDA announced the appointment of Frank M. Torti, MD, as its principal deputy commissioner and first chief scientist.

Dr. Torti, who has written extensively on prostate and bladder cancer, is responsible for ensuring the quality and regulatory focus of the intramural research programs of the agency, with emphasis on clinical research trials.

He serves on the National Institutes of Health National Advisory Council for Complementary and Alternative Medicine, and is president of the Cancer Biology Training Consortium. He also is an NIH MERIT Award recipient.

Dr. Torti is the Charles L. Spurr Professor of Medicine, chair of the department of cancer biology, and director of the comprehensive cancer center at Wake Forest University School of Medicine in Winston-Salem, NC. He previously was on the faculty at Stanford University, Stanford, CA.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
David Barquin, MD, answers a question during a Zoom video interview
Alexandra Tabakin, MD, answers a question during a Zoom video interview
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.